Synthesis,Crystal Structure and Density Functional Theory Studies of 9-Hexyl-3-（（pyridin-4-yl）vinyl）-9H-carbazol

A novel pyridine derivate, 9-hexyl-3-（（pyridin-4-yl）vinyl）-9H-carbazole, was synthesized and characterized by 1H NMR spectra and X-ray diffraction analysis. The complex crystallizes in monoclinic, space group P21/n with a = 9.111（5）, b = 8.239（5）, c = 26.835（5） A, β = 95.340（5）°, Mr = 354.48, V = 2005.6（17） A3, Z = 4, Dc = 1.174 g/cm3,μ = 0.068 mm^-1, F（000） = 760, R = 0.0565 and wR = 0.1550 for 12635 observed reflections （I 〉 2σ（I））. Density functional theory （DFT） calculations were carried out to interpret its UV-Vis spectra, and the results are in agreement with the available experiments.     

Synthesis and Crystal Structure of (Z)-4-(p-Bromo phenylthio)-3-(p-nitrobenzoyloxy)-3-buten-2-one

１　ＩＮＴＲＯＤＵＣＴＩＯＮＩｎｏｒｄｅｒｔｏｅｖａｌｕａｔｅｔｈｅｓｅｌｅｃｔｉｖｉｔｙａｎｄｒｅａｃｔｉｖｉｔｙｏｆｅｎｏｎｅｓａｓｄｉｅｎｏｎｅｐｈｉｌｅｓａｎｄｄｉｅｎｅｓｉｎＤｉｅｌｓＡｌｄｅｒｒｅａｃｔｉｏｎ,Ｐａｒａｌｔａｓｙｎｔｈｅｓｉｚｅｄβｆｕｎｃｔｉｏｎａｌｉｚｅｄｌａｃｅｔｙｌｖｉｎｙｌａｒｅｎｅｃａｒｂｏｘｙｌａｔｅｓａｓａｓｕｂｓｔｒａｔｅｏｆ１,３ｄｉｐｏｌａｒｃｙｃｌｏａｄｄｉｏｎｒｅａｃｔｉｏｎ〔１〕．Ｘｒａｙｃｒｙｓｔａｌｌｏｇｒａｐｈｉｃｓｔｕｄ…     

Synthesis and Crystal Structure of [NiL_2(H_2O)_2](ClO_4)_2L=MBPT=4-P-methylphenyl-3,5-bis-(pyridin-2-yl)-1,2,4-triazole

The substituted l,2,4-triazoles are very useful ligands in coordination chemistry'-'. It isvery interesting that some complexes containing substituted l,2,4-triazoles ligands havethe spin-crossover phenomena, which could be used as magnetic materials4-5. However,complexes containing triaryltriazole ligands have been little known so far. We haverecently synthesized some triaryltriazole compounds'-', and we first report here thesynthesis and crystal structure of [Ni(MBPT),(H,O),](CIO.),.Expe…     

Microwave Assistant Synthesis and Dimeric Crystal Structure of 2-(((6-Chloropyridin-3-yl)-methyl)thio)-5-(pyridin-4-yl)-1,3,4-thiadiazole

The title compound 2-(((6-chloropyridin-3-yl)methyl)thio)-5-(pyridin-4-yl)-1,3,4-thiadiazole 5(C26H18Cl2N8S4) was synthesized, and its structure was confirmed by 1H NMR, MS and elemental analyses and X-ray diffraction. It crystallizes in the triclinic system, space group P1 with a = 9.452(4), b = 12.335(4), c = 13.017(5) A, α = 90.624(5), β = 110.541(5), γ =104.879(4)°, Dc = 1.561 g/cm3, Z = 2, V = 1364.9(9) A3, F(000) = 656, the final R = 0.0300 and w R = 0.0635 for 4206 observed reflections with I 2σ(I). The preliminary biological test showed that the title compound has activities against Stemphylium lycopersici(Enjoji) Yamamoto, Fusarium oxysporum. sp. cucumebrium, and Botrytis cinerea with inhibitory activities to be 9.82%, 44.44% and 20.00%, respectively.     

Synthesis,crystal structure,antiproliferative activity,DNA binding and density functional theory calculations of 3-(pyridin-2-yl)-8-tert-butylcoumarin and its copper(II) complex

A Cu(II)–coumarin complex, [CuL₂(NO₃)₂] ( 2 ), where L = 3-(pyridin-2-yl)-8-tert-butylcoumarin ( 1 ), was synthesized with Cu(NO₃)₂⋅3H₂O and characterized using elemental, infrared and single-crystal X-ray diffraction analyses. The crystal structure of 1 shows that all the pyrone, benzene and pyridine rings are completely coplanar. The crystal structure of 2 is stabilized by intermolecular C–H···O and C–H···N hydrogen bonds and C···C short contacts, which lead to the formation of a two-dimensional network structure. Density functional theory results give support to the experimentally determined monomeric structure. The in vitro cytotoxic activities of 1 and 2 were investigated against HeLa (cervical carcinoma), A549 (lung), HepG2 (liver) and HUVEC (umbilical vein) cells by MTT assay. The IC₅₀ values show that both 1 and 2 have lower toxicity than doxorubicin and cisplatin in every case. Ligand 1 exhibits higher anti-HeLa activity than doxorubicin. Complex 2 displays higher anti-HeLa activity than coumarin but lower than that of cisplatin. Various spectroscopic approaches indicate that 1 and 2 could effectively bind with DNA through intercalation mode.     

新的含有4-对甲基苯基-3，5-二(2-吡啶基)-1，2，4-三氮唑钴配合物的合成和晶体结构(英)

A new cobalt(Ⅱ) complex, [CoL₂(NCS)₂]·2CH₂Cl₂, [L=4-(p-methylphenyl)-3,5-bis(pyridin-2-yl)-1,2,4-triazole], was synthesized and its crystal structure was determined by X-ray analysis. The complex crystallizes in monoclinic system with space group P2₁/c, a=0.867 40(17), b=1.453 9(3), c=1.781 9(4) nm, β=91.18(3)°, V=2.246 7(8) nm³ and Z=2. The cobalt atom is in a distorted octahedral environment with two bidentate chelating L ligands in the equatorial plane and two NCS^- ions in the axial positions. CCDC: 251658.     

Synthesis and Crystal Structure of Dimethyl-3-（4-bromophenyl）-1-phenyl-4,5-dihydro-1H-pyrazole-4,5-dicarboxylate

The title compound (C19H17BrN2O4) was synthesized via a one-pot procedure starting from 4-bromobenzaldehyde, dimethyl acetylenedicarboxylate (DMAD) and phenylhydrazine with pyridine as the catalyst. Its structure was determined by single-crystal X-ray diffraction analysis. The crystal belongs to the monoclinic system, space group P21/c with a = 11.115(3), b = 8.090(2), c = 20.211(5) , β = 97.032(5)°, V = 1803.7(8) 3, Z = 4, Mr = 417.25, Dc = 1.536 g/cm3, μ = 2.306 mm-1, F(000) = 852, the final R = 0.0403 and wR = 0.0895 for 2215 observed reflections with I 2σ(I).     

Synthesis and Crystal Structure of {4-[2-（9- Hexyl-9H-carbazol-3-yl）vinyl]phenyl} Dimethylamine

The title compound {4-[2-(9-hexyl-9H-carbazol-3-yl)vinyl]phenyl} dimethylamine has been synthesized by the well known Wittig reaction, and its crystal structure was determined by single-crystal X-ray diffraction analysis. It crystallizes in monoclinic, space group P21/c with a = 47.87(2), b = 10.222(4), c = 9.612(4) , β = 92.401(9)o, V = 4699(3) 3, Z = 8, C28H32N2, Mr = 396.56, Dc = 1.121 g/cm3, F(000) = 1712 and μ(MoKa) = 0.065 mm-1. The final R and wR are 0.0793 and 0.1983, respectively for 3524 observed reflections with I > 2σ(I). In the title compound, the bond lengths are normal, and the crystal is stabilized by Van der Waals’ forces.     

Synthesis and Crystal Structure of N-(1,3,4-Thiadiazol-2-yl)-1-[1-(6-chloropyridin-3-yl)methy]-5-methyl-1H-[1,2,3]triazol-4-carboxamide

The crystal structure of the title compound (C12H10ClN7OS,Mr=335.78) has been determined by single-crystal X-ray diffraction. The crystal is of triclinic,space group P1 with a=8.4093(11),b=9.4430(12),c=11.1454(14),α=95.508(2),β=111.366(2),γ=115.259(2)°,V=711.42(16) 3,Z=2,Dc=1.568 g/cm3,F(000)=344,μ(MoKα)=0.428 mm-1,the final R=0.0476 and wR=0.1243 for 2353 observed reflections (I > 2σ(I)). The dihedral angles between the pyridine and triazole,thiazole and triazole,and pyridine and thiazole rings are 69.2(1),9.2(1) and 72.7(1)o,respectively. Intramolecular C(8)-H(8B)…O(1) and N(5)-H(5A)…N(4) as well as intermolecular C(5)-H(5)…S(1),C(3)-H(3)…N(6) and N(5)-H(5A)…N(1) hydrogen bonds together with weak C-H…π hydrogen-bonding and π-π stacking interactions contribute to the stability of the structure. There is also evidence for significant electron delocalization in the triazolyl system.     

Synthesis and Crystal Structure of （E）-4-（3-oxo-3-（（4- （N-（pyrimidin-2-yl）-sulfamoyl）phenyl）amino）prop- 1-en-l-yl）-l,2-phenylene diacetate Dimethanol

The title compound, (E)-4-(3-oxo-3-((4-(N-(pyrimidin-2-yl)sulfamoyl)-phenyl)ami- no)prop- 1-en- 1-yl)- 1,2-phenylene diacetate dimethanol, was synthesized by the reaction of caffeic acid with sulfadiaz...     

3-[3-甲氧基-4-(2-乙氧基-2-氧代乙氧基)苯基]丙烯酸乙酯的合成及其晶体结构

以香草醛为原料,经Williamsom反应和Knoevenagel-Doebner反应制得新化合物3-(3-甲氧基-4-羧甲氧基苯基)丙烯酸(2);2与乙醇经酯化反应合成了阿魏酸衍生物——3-[3-甲氧基-4-(2-乙氧基-2-氧代乙氧基)苯基]丙烯酸乙酯(3),其结构经1H NMR,IR,元素分析和X-射线单晶衍射确证。3属三斜晶系,空间群P-1,晶胞参数a=8.301,b=8.474,c=11.445,α=82.94°,β=86.86°,γ=84.52°,V=794.63,Z=2,Dc=1.289 g·cm-3,R1=0.046 7,wR2=0.101 8。3通过分子间氢键(C-H┈O)形成了二维网状结构。     

Synthesis and Crystal Structure of 4,6-Di-tert-butyl-2-hydroxy-3-(N-1-phenylethyliminomethyl)phenyl bis(triphenylphosphine)palladium bromide

１ＩＮＴＲＯＤＵＣＴＩＯＮＰａｌａｄｉｕｍｃｏｍｐｌｅｘｅｓｓｕｃｈａｓｔｅｔｒａｋｉｓ（ｔｒｉｐｈｅｎｙｌｐｈｏｓｐｈｉｎｅ）ｐａｌａｄｉｕｍａｒｅａｋｉｎｄｏｆｉｍｐｏｒｔａｎｔｃａｔａｌｙｓｔｓｉｎｔｈｅｒｅａｃｔｉｏｎｏｆｃａｒｂｏｎ ｃａｒ...     

Synthesis,Crystal Structure and Anticoagulant Activity of 5-Chloro-N-[[（5S）-2-oxo-3-[4-（2- oxopyridin-1 （2H）-yl）phenyl] oxazolidin-5- yl] methyl] thiophene-2-carboxamide①

The title compound(zifaxaban 2, C20H16ClN3O4 S, Mr = 429.87) was synthesized and its crystal structure was determined by single-crystal X-ray diffraction. Zifaxaban crystallizes in monoclinic, space group P21 with a = 5.7900(12), b = 13.086(3), c = 12.889(3) A, β = 100.86(3)°, V = 959.1(3) A3, Z = 2, Dc = 1.489 g/cm3, F(000) = 444, μ = 0.342 mm-1, the final R = 0.0320 and wR = 0.0640 for 2717 observed reflections(I 2σ(I)). The absolute configuration of the stereogenic center in the title compound was confirmed to be S by single-crystal X-ray diffraction. Four existing intermolecular hydrogen bonds help to stabilize the lattice and the molecule in the lattice to adopt an L-shape conformation. Zifaxaban was slightly more active than rivaroxaban 1 in in vitro assay against human FXa and therefore is promising as a drug candidate.     

Synthesis and Crystal Structure of 2-p-Methyloxyphenyl- 3a-（2-phenyl-1,2,3-triazole-4-yl）-3,4-dihydro-1,2,4- oxa-diazolo[4,5-d][1,5] Benzothiazepine

The title compound2-p-methyloxyphenyl-3a-(2-phenyl-1,2,3-triazole-4-yl)-3,4- dihydro-1,2,4-oxa-diazolo[4,5-d][1,5] benzothiazepine (C31H25N5O2S, Mr = 531.63) has been syn- thesized and its structure was determined by single-crystal X-ray diffraction. The crystal belongs to triclinic, space group P1 with a = 10.888(2), b = 15.115(3), c = 16.702(3), α = 99.90(3), β = 95.21(3), γ = 100.41(3)o, V = 2642.1(9) nm3, Dc = 1.336 g/cm3, Z = 4, F(000) = 1112, μ = 0.162 mm-1 ,λ(MoKα) = 0.071073 nm, R = 0.0357 and wR = 0.1126 for 10620 observed reflections with I > 2σ(I). X-ray analysis reveals that the molecular backbone consists of a tricyclic system with the central seven- membered ring in a twisted boat-like conformation.     

N-[2,6-二氯-4-(1,2,4-噁二唑-3-基)苯基]-2-甲氧基烟酰胺的合成、晶体结构及抗肿瘤活性研究

报道一种新型1,2,4-噁二唑衍生物,N-[2,6-二氯-4-(1,2,4-噁二唑-3-基)苯基]-2-甲氧基烟酰胺（C15H10Cl2N4O3）的合成,其结构通过1H NMR、13C NMR、HRMS以及X-射线单晶衍射进行表征。该晶体结构属于三斜晶系, P 1(—) 空间群,晶胞参数 a = 7.1291 (9), b = 8.4352 (10), c = 14.0021 (18) ?, α = 73.834 (3), β = 77.407 (3), γ = 70.019 (3)°, Mr = 366.18, V = 752.97 (16) ?3, Z = 2, Dc = 1.611 g/cm3, μ(MoKα) = 0.454 mm-1, F(000) = 372.0 , 晶体尺寸为 0.36 × 0.2 × 0.1 mm,Rint = 0.023。初步活性研究发现,该化合物对LoVo, A549, SK-BR-3, HeLa这四种肿瘤细胞株具有明显的抑制作用,尤其是对HeLa细胞的抑制活性与阳性药物5-氟尿嘧啶 (5-FU)相当。     

[Cu(HIm)_2(PPh_3)_2](BF_4)的合成与晶体结构

铜?配合物以结构多样化、生物和医药活性和独特的光谱性能而成为活跃的研究领域,其合成、结构以及性能的研究已受到日益广泛的重视,它们与普通配体的分子设计和结构测定涉及生物无机化学,无机合成和金属基药物设计等内容犤１,２犦。咪唑衍生物是常见的生物配体,对生物功能起重要的作用,咪唑氮原子与金属离子配位成键,形成各种金属生物分子的活性中心,通过了解金属与咪唑氮原子配位的结构特点,建立生物活性结构模型配合物,可以达到研究金属酶活性中心结构与物性关系的目的犤３,４犦。生物体中大部分铜与两种以上配体形成混配配合…     

基于3-吡唑-5吡啶-1,2,4-三唑和均苯四甲酸构筑的两个同构配位聚合物的晶体结构和磁性

以3-吡唑-5吡啶-1,2,4-三唑(H2L)和均苯四甲酸(H_4btec)为配体合成了2个新的同构配位聚合物[M(btec)_(0.5)(H_2L)]_n(M=Co(Ⅱ)(1),Cu(Ⅱ)(2)),通过X射线单晶衍射、元素分析、红外光谱等进行了结构表征。晶体结构分析表明配合物1和2是同构的,都属于正交晶系,空间群为Pbca。2个配位聚合物都是二维结构,通过N…H…O氢键形成三维超分子框架结构。此外对上述配合物进行了磁性研究,结果表明配合物1内通过羧基桥连的金属钴离子之间是弱的铁磁相互作用;配合物2中存在典型的順磁行为。     

Synthesis, Crystal Structure and Properties of 2,7-Bis [4-（diphenylamino）phenyl] fluorene

A novel fluorene derivative containing triphenylamine groups, 2,7-bis[4-(diphenylamino)-phenyl]fluorene (C49H36N2 , Mr= 652.80), was synthesized via Suzuki coupling reaction (yield: 19%) and its crystal structure was determined by single-crystal X-ray diffraction. It crystallizes in triclinic, space group P1 with a = 9.320(4), b = 11.250(6), c = 17.369(6) , α = 88.035(3), β = 86.450(5), γ = 73.524(5)°, V = 1742.8(13) 3 , Z = 2, Dc = 1.244 g/cm 3 , μ(MoKα) = 0.072 mm -1 , F(000) = 688, S = 1.095, the final R = 0.0616 and wR = 0.1878. It presents a linear framework constituted by a linkage of fluorene as a bridge and two triphenylamine groups. Its spectral and electrochemical properties were studied by UV-Vis absorption, fluorescence spectroscopy and cyclic voltammetry (CV). This compound can emit intense blue fluorescence with a peak wavelength of 446 nm and a full width at half maximum (FWHM) of 38 nm under UV excitation at 350 nm in film. The highest occupied molecular orbital (HOMO) energy level, the lowest unoccupied molecular orbital (LUMO) energy level and optical band gap (Eg) of the title compound are -5.46, -2.57 and 2.89 eV, respectively.     

X-ray studies of three 3,6-bis(pyridin-2-yl)-1,2,4,5-tetrazine cocrystals: an unexpected molecular conformation stabilized by hydrogen bonds

The results of the X-ray structure analysis of three novel 3,6-bis(pyridin-2-yl)-1,2,4,5-tetrazine cocrystals are presented. These are 3,6-bis(pyridin-2-yl)-1,2,4,5-tetrazine–2,4,6-tribromophenol (1/2), C₁₂H₈N₆·2C₆H₃Br₃O, 3,6-bis(pyridin-2-yl)-1,2,4,5-tetrazine–isonicotinic acid N-oxide (1/2), C₁₂H₈N₆·2C₆H₅NO₃, and 3,6-bis(pyridin-2-yl)-1,2,4,5-tetrazine–4-nitrobenzenesulfonamide (1/1), C₁₂H₈N₆·C₆H₆N₂O₄S. Special attention is paid to a conformational analysis of the title tetrazine molecule in known crystal structures. Quantum chemistry methods are used to compare the energetic parameters of the investigated conformations. A structural analysis of the hydrogen and halogen bonds with acceptor aromatic tetrazine and pyrazine rings is conducted in order to elucidate factors responsible for conformational stability.